3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
Specimen Handling
321
Magnetic Resonance Spectroscopy
275
pembrolizumab
267
Carboplatin
190
Cyclophosphamide
185
Biopsy
178
Cisplatin
164
Gemcitabine
139
Paclitaxel
137
Bevacizumab
123
fludarabine
122
Nivolumab
117
Radiotherapy
113
Oxaliplatin
94
venetoclax
92
Docetaxel
90
Fluorouracil
88
Capecitabine
88
Dexamethasone
85
Drug Therapy
76
Pemetrexed
75
Rituximab
73
durvalumab
71
Leucovorin
71
Blood Specimen Collection
70
Radiosurgery
69
Standard of Care
67
atezolizumab
64
Doxorubicin
64
Radiation
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Histamine Antagonists
×
90 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled